Bacteriological profile and drug susceptibility patterns in dacryocystitis patients attending Gondar University Teaching Hospital, Northwest Ethiopia

Assefa, Yared; Moges, Feleke; Endris, Mengistu; Zereay, Banchamlak; Amare, Bemnet; Bekele, Damtew; Tesfaye, Solomon; Mulu, Andargachew; Belyhun, Yeshambel

doi:10.1186/s12886-015-0016-0

Table 3 Antimicrobial susceptibility test patterns of bacterial pathogens isolated from dacryocystitis infection, University of Gondar Eye Specialized Hospital, Northwest Ethiopia, Gondar, Ethiopia from 2011 to 2012

From: Bacteriological profile and drug susceptibility patterns in dacryocystitis patients attending Gondar University Teaching Hospital, Northwest Ethiopia

Bacterial isolates	No. (%)	Pattern	Common antibiotics tested, No. (%)
Bacterial isolates	No. (%)	Pattern	AMP	AMOX	CIP	CN*	MET*	NA	CAF	ERY*	PEN*	TTC	SXT	CEF
S .aureus	6(19.4)	S	5(83.3)	5(83.3)	6(100.0)	-	5(83.3)	6(100.0)	6(100.0)	4(66.7)	4(66.7)	3(50.0)	4(66.7)	6(100.0)
S .aureus	6(19.4)	R	1(16.7)	1(16.7)	0(0.0)	-	1(16.7)	0(0.0)	0(0.0)	2(33.3)	2(33.3)	3(50.0)	2(33.3)	0(0.0)
CNS	9(29.0)	S	9(100.0)	7(77.8)	5(55.6)	-	9(100.0)	9(100.0)	7(77.8)	9(100)	6(66.7)	7(77.8)	6(66.7)	8(88.9)
CNS	9(29.0)	R	0(0.0)	2(22.2)	4(44.4)	-	0(0.0)	0(0.0)	2(22.2)	0(0.0)	3(33.3)	2(22.2)	3(33.3)	1(11.1)
S. pnemoniae	2(6.5)	S	0(0.0)	2(100.0)	1(50.0)	-	2(100.0)	2(100.0)	1(50.0)	2(100)	2(100)	0(0.0)	2(100)	2(100)
S. pnemoniae	2(6.5)	R	2(100.0)	0(0.0)	1(50.0)	-	0(0.0)	0(0.0)	1(50.0)	0(0.0)	0(0.0)	2(100.0)	0(0.0)	0(0.0)
Entrobacter spp.	2(6.5)	S	2(100.0)	1(50.0)	1(50.0)	-	-	0(0.0)	1(50.0)	1(50.0)	1(50.0)	2(100.)	0(0.0)	2(100)
Entrobacter spp.	2(6.5)	R	0(0.0)	1(50.0)	1(50.0)	-	-	2(100.0)	1(50.0)	1(50.0)	1(50.0)	0(0.0)	2(100)	0(0.0)
E .coli	1(3.2)	S	1(100.0)	0(0.0)	1(100.0)	1(100.0)	-	0(0.0)	1(100.0)	-	-	0(0.0)	1(100)	1(100)
E .coli	1(3.2)	R	0(0.0)	1(100)	0(0.0)	0(0.0)	-	1(100.0)	0(0.0)	-	-	1(100.0)	0(0.0)	0(0.0)
K. pnemoniae	2(6.5)	S	1(50.0)	1(50.0)	2(100.0)	2(100.0)	-	1(50.0)	2(100.0)	-	-	1(50.0)	2(100.)	1(50.0)
K. pnemoniae	2(6.5)	R	1(50.0)	1(50.0)	0(0.0)	0(0.0)	-	1(50.0)	0(0.0)	-	-	1(50.0)	0(0.0)	1(50.0)
Pseudomonas spp.	3(9.7)	S	2(66.7)	1(33.3)	2(66.7)	2(66.7)	-	2(66.7)	2(66.7)	-	-	2(66.7)	2(66.7)	3(100.)
Pseudomonas spp.	3(9.7)	R	1(33.3)	2(66.7)	1(33.3)	1(33.3)	-	1(33.3)	1(33.3)	-	-	1(33.3)	1(33.3)	0(0.0)
Citrobacter spp.	1(3.2)	S	1(100.0)	1(100.0)	1(100.0)	1(100.0)	-	1(100.0)	1(100.0)	-	-	1(100)	1(100)	1(100)
Citrobacter spp.	1(3.2)	R	0(0.0)	0(0.0)	0(0.0)	0(0.0)	-	0(0.0)	0(0.0)	-	-	0(0.0)	0(0.0)	0(0.0)
H.influenzae	2(6.5)	S	2(100.0)	0(0.0)	2(100.0)	2(100.0)	-	2(100.0)	1(50.0)	-	-	1(50.0)	1(50.0)	2(100.0)
H.influenzae	2(6.5)	R	0(0.0)	2(100)	0(0.0)	0(0.0)	-	0(0.0)	1(50.0)	-	-	1(50.0)	1(50.0)	0(0.0)
P.vulgaris	1(3.2)	S	1(100.0)	0(0.0)	1(100.0)	1(100.0)	-	1(100.0)	1(100.0)	-	-	1(100)	1(100)	1(100)
P.vulgaris	1(3.2)	R	0(0.0)	1(100)	0(0.0)	0(0.0)	-	0(0.0)	0(0.0)	-	-	0(0.0)	0(0.0)	0(0.0)
P. mirabilis	1(3.2)	S	0(0.0)	0(0.0)	1(100.0)	1(100.0)	-	1(100.0)	0(0.0)	-	-	1(100.0)	1(100)	1(100)
P. mirabilis	1(3.2)	R	1(100)	1(100)	0(0.0)	0(0.0)	-	0(0.0)	1(100)	-	-	0(0.0)	0(0.0)	0(0.0)
Providencia spp	1(3.2)	S	1(100.0)	0(0.0)	1(100.0)	0(0.0)	-	1(100.0)	1(100.0)	-	-	0(0.0)	0(0.0)	1(100)
Providencia spp	1(3.2)	R	0(0.0)	1(100)	0(0.0)	1(100)	-	0(0.0)	0(0.0)	-	-	1(100)	1(100)	0(0.0)
Total	31(100)	S	25(80.6)	19(61.3)	23(74.2)	10(83.3)	17(89.5)	27(87.1)	23(74.2)	16(84.2)	13(68.4)	22(71.0)	23(74.2)	29(93.5)
Total	31(100)	R	6(19.4)	12(38.7)	8(25.8)	2(16.7)	2(10.5)	4(12.9)	8(25.8)	3(15.8)	6(31.6)	6(29.0)	8(25.8)	2(6.5)

Keys: AMP- Ampicillin, AMOX-Amoxicillin, CIP- Ciprofloxacin, CN- Gentamycin, MET- Methicillin, NA-Nalidic Acid, CAF-Chloramphinicol, ERY- Erythromycin, VAN- Vancomycin, PEN-penicillin, TTC- Tetracycline, SXT- Co-trimoxazole, CEF-Ceftriaxone. *Percentage calculation is based on column total [19] denominator.

Back to article page

ISSN: 1471-2415

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Ophthalmology

Contact us